Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications.

ABSTRACT: As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence and clinical symptoms, challenges regarding practicality and accessibility hinder their widespread availability and implementation. Consequently, many people with suspected cognitive impairment due to AD do not receive a biomarker-supported diagnosis. Blood biomarkers have the capacity to help expand access to AD diagnostics worldwide. One such promising biomarker is plasma phosphorylated tau (p-tau), which has demonstrated specificity to AD versus non-AD neurodegenerative diseases, and will be extr

SUBMITTER: Gonzalez-Ortiz F 

PROVIDER: S-EPMC10022272 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature